Antidepressant withdrawal-induced activation (hypomania and mania): Mechanism and theoretical significance

Brain Research Reviews

Volumn 7, Issue 1, 1984, Pages 29-48

  Dilsaver, Steven C ^a   Greden, John F ^b  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

affective disorders antidepressants cholinergic depression mania monoamines muscarinic tricyclics

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; BENZATROPINE MESILATE; BRAIN MONOAMINE; CARBACHOL; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; DRONABINOL; NORADRENALIN; PENTOBARBITAL; PHYSOSTIGMINE; PLACEBO; TIOTIXENE; TRAZODONE; NEUROTRANSMITTER; NEUROTRANSMITTER RECEPTOR;

CENTRAL NERVOUS SYSTEM; DRUG THERAPY; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; ETIOLOGY; HUMAN; HYPOMANIA; MANIA; ORAL DRUG ADMINISTRATION; REVIEW; THERAPY; WITHDRAWAL; WITHDRAWAL SYNDROME; ADRENERGIC NERVE; ANIMAL; ANIMAL BEHAVIOR; AROUSAL; BIPOLAR DISORDER; BRAIN; CHOLINERGIC NERVE; DRUG EFFECT; EVOKED RESPONSE; IATROGENIC DISEASE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SLEEP STAGE;

ADRENERGIC FIBERS; ANIMAL; ANTIDEPRESSIVE AGENTS; AROUSAL; BEHAVIOR, ANIMAL; BIPOLAR DISORDER; BRAIN; CHOLINERGIC FIBERS; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS; HUMAN; NEUROTRANSMITTERS; RECEPTORS, NEUROTRANSMITTER; SLEEP STAGES; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0021399370     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/0165-0173(84)90028-6     Document Type: Review

References (206)

1. Electroconvulsive shock, brain acetylcholinesterase activity and memory
2. Locomotor activity stimulation in rats produced by dopamine in the nucleus accumbens, potentiation by caffeine
3. Effects of single injections of nicotine in the ascending dopamine pathways in the rat. Evidence for increases of dopamine turnover in neostriatal and mesolimbic dopamine neurons
4. The action of cholinergic agents on the electrical activity of the non-specific nuclei of the thalamus
5. Neuroendocrine evidenced for increased responsiveness of dopamine receptors in humans following electroconvulsive therapy
6. Eserine and amphetamine: interactive effects on sleeping time in mice
7. Effect of amantadine on cerebral acetylcholine release and content on the guinea pig
8. The cerebral acetylcholine release in conscious rabbits with semi-permanently implanted epidural cups
9. Receptors, adenylate cyclase, depression and lithium
10. Scopolamine induces an increase in muscarinic receptor level in rat hippocampus
11. Adrenergic and serotonergic receptor binding in rat brain after chronic desmethylimipramine treatment
12. Effect of lithium ions on the release of acetylcholine from the cerebral cortex
13. Psychiatric manifestations of artane toxicity
14. Some behavioral changes in man following anticholinesterase administration
15. The effect of atropine, hyoscyamine, physostigmine and neostigmine on the electrical activity of the brain of a conscious cat
16. The effects of some drugs on the electrical activity of the brain
17. The effect of drugs on arousal responses produced by electrical stimulation of the reticular formation of the brain
18. Effects of atropine and related drugs on the EEG and behavior
19. Action of intrathecally injected prostigmine, acetylcholine and eserine on the central nervous system in man
20. Acetylcholine et cortex cerebral
21. Norepinephrine in depressive reactions
22. A second generation catecholamine hypothesis
23. Antischizophrenic drugs: Chronic treatment elevates dopamine receptor binding in brain
24. Ontogeny of adrenergic arousal and cholinergic inhibiting mechanisms in the rat
25. Cholinergic reversal of manic symptoms
26. Neurotransmitter studies of neuroendocrine pathology in depression
27. A specific laboratory test for the diagnosis of melancholia
28. Receptor sensitivity and the mechanism of action of antidepressant treatment
29. Abrupt discontinuation of tricyclic antidepressant drugs: evidence for noradrenergic hyperactivity
30. Repeated tricyclics induce progressive dopamine autoreceptor subsensitivity independent of daily drug treatment
31. Electroconvulsive shock, progressive dopamine autoreceptor subsensitivity independent of repeated treatment
32. Do antidepressants induce dopamine autoreceptor subsensitivity?
33. Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration
34. Changes in α- and β-receptor densities in rat brain as a result of treatment with monoamine oxidase inhibiting antidepressants
35. Visualization of 'C-flunitrazepam displacement in the brain of the live baboon
36. Brain distribution and kinetics of 'C-Chlorpromazine in schizophrenics
37. Biochemistry of affective disorders
38. The behavioral effects of dopamine applied intracerebrally to areas of the mesolimbic system
39. Receptor adaptations to centrally acting drugs
40. Presynaptic α-receptor subsensitivity after long-term antidepressant treatment
41. Parasympathetic regulation of high potential in the electroencephalogram
42. Evidence for an agonist independent down-regulation of hippocampal muscarinic receptors in kindling
43. Seizures down-regulate muscarinic cholinergic receptors in hippocampal formation
44. Antidepressant withdrawal syndromes: evidence supporting the cholinergic overdrive hypothesis
45. Antidepressant withdrawal symptoms treated with anticholinergic agents
46. Antidepressant withdrawal syndromes: evidence for supersensitivity of the cholinergic system as an etiologic factor
47. Antidepressant withdrawal phenomena: a review
48. Physostigmine-induced escape from dexamethasone in normal subjects
49. The effects of bromocriptine on locomotor activity and cerebral catecholamines in rodents
50. Social drugs
51. Physostigmine and lithium response in the schizophrenias
52. 3H]quinuclidinyl benzilate binding in the striatum of rats following chronic cholinesterase inhibition with diisopropylflurophoshonate
53. Dopaminergic regulation of muscarinic receptor binding in the corpus striatum
54. Induction of severe depression by physostigmine in marijuana intoxicated individuals
55. The nature of muscarinic receptor binding
56. A double-blind placebocontrolled study of bupropion hydrochloride (Wellbutrin) in the treatment of depressed inpatients
57. Cholinergic suppression of tardive dyskinesia
58. Clinical efficacy of the newer antidepressants
59. Dissociation of electrocortical activation and behavioral arousal
60. Cholinergic modulation of adrenergic arousal in the developing cat
61. A biphasic action of central cholinergic stimulation on behavioral arousal in the rat
62. Cholinergic aspects of convulsive therapy
63. Behavior during hippocampal microinfusions. I. Norepinephrine and diversive explorations
64. Behavior during hippocampal microinfusions. II. Muscarinic locomotor activation
65. Behavior during hippocampal microinfusions. III. Lidocaine versus picrotoxin
66. Behavior during hippocampal microinfusions. IV. Transmitter interactions
67. Central nervous system stimulants
68. A dopaminergic-cholinergic mechanism in the production of psychotic symptoms
69. Platelet β-adrenergic receptors in major depressive disorder
70. Administration of an organophosphate causes a decrease in muscarinic receptor levels in rat brain
71. Acholinergic mechanism in the brain stem reticular formation: induction of paradoxical sleep
72. Psychiatric sequelae of chronic exposure to organophosphorus insecticides
73. Electroconvulsive treatment: rapid subsensitivity of the norepinephrine receptor coupled adenylate cyclase system in brain linked to down-regulation of β-adrenergic receptors
74. Muscarinic supersensitivity: a possible model for the sleep disturbance of primary depression?
75. Serial dexamethasone suppression tests among rapidly cycling bipolar patients
76. Dexamethasone suppression tests in antidepressant treatment of melancholia
77. The administration of diisopropylfluorophosphate (DFP) to man
78. Limbic cholinergic pathways involved in sleep and emotional behavior
79. Dopamine binding following prolonged haloperidol pretreatment
80. The cellular basis of sleep cycle control
81. Selective firing by cat pontine brain stem neurons in desynchronized sleep
82. Sleep cycle oscillation: Reciprocal discharge by two brainstem neuronal groups
83. The reciprocal interaction model of sleep cycle control: a discussion in the light of Giuseppe Moruzzi's concepts
84. Effects of caffeine, methamphetamine and methylphenidate on reaction to novelty and activity in rats
85. A functional effect of dopamine in the nucleus accumbens and in some other dopamine-rich parts of the rat brain
86. Drug addiction and drug abuse
87. A cholinergic adrenergic hypothesis of mania and depression
88. Cholinergic antagonism of methylphenidate-induced stereotyped behavior
89. Acetylcholine and depression
90. Parasympathetic suppression of manic symptoms by physostigmine
91. Antagonistic effects of physostigmine and methylphenidate in man
92. Antagonism of cholinergic inhibition by lithium
93. Increased vulnerability to cholinergic stimulation in affect disorder patients
94. The influence of lithium on cholinergic function
95. Behavioral effects of physostigmine in affective disorder patients
96. Acetylcholine liberation from cerebral cortex during paradoxical (REM) sleep
97. Mood elevating effect of trihyxyphenidyl and biperiden in individuals taking antipsychotic medication
98. Therapeutic strategies against tardive dyskinesia: two decades of experience
99. Erythrocyte choline and manic depressive disorder and the effect of lithium: a study with NMR techniques
100. Biphasic locomotor response to intra-accumbens dopamine in a nonhuman primate
101. Circadian and seasonal rhythms in α- and β-adrenergic receptors in rat brain
102. Circadian acetylcholine receptor rhythm in rat brain and its modification by imipramine
103. Effect of lithium on circadian neurotransmitter receptor rhythms
104. Trihyxyphenidyl (artane) abuse: euphoriant and anxiolytic
105. Mesencephalic reticular activating system and cortical acetylcholine output
106. Norepinephrine synthesis and turnover in the brain: acceleration by physostigmine
107. Principles of toxicology
108. 9tetrahydrocannibinol on excitable membranes and neuromuscular transmission
109. Adverse interaction between disulfiram and marijuana: a case report
110. 1tetrahydrocannabinol and cannabinoid at cholinergic functions
111. Reduced presynaptic dopaminereceptor density after chronic antidepressant treatment in rats
112. Receptors and the mechanism of action of ECT
113. Effect upon the EEG of acute injury to the brain stem activating system
114. Action of eserine and amphetamine on the electrical activity of the rabbit brain
115. Effects of scopolamine and atropine on electroencephalographic and behavioral reactions due to hypothalamic stimulation
116. Behavioral and electroencephalographic effects of atropine and related compounds
117. Effect of single and repeated electroshock applications on brain acetylcholine levels and choline acetyltransferase activity in the rat
118. Depolarization-induced changes in muscarinic cholinergic receptors in synaptosomes
119. Caudal and cephalic influences of the brain reticular formation
120. Positron tomography, A new method for in vivo brain studies of benzodiazepine receptors in animal and in man
121. Single neuron activity in cat gigantocellular tegmental field: selectivity of discharge in desynchronized sleep
122. Convulsive seizures and electroencephalogram changes in three patients during levodopatherapy
123. Abuse of antiparkinson drug by psychiatric patients
124. Some effects of muscarinic cholinergic blockings drugs on behavior and the electrocorticogram
125. The local action of eserine on the central nervous system
126. Effects of eserine, acetylcholine and atropine on the electrocorticogram
127. Hypomania and mania after withdrawal of tricyclic antidepressants
128. Zur frageder beeinflussung schizophrener symptome durch physostigmine
129. Cholinergic mechanisms involved in cortical activation during arousal
130. Brain stem reticular formation and activation of the EEG
131. Regulation of catecholamine release, The muscarinic inhibitory mechanism
132. Dopamine receptor binding in rat striatum: ultradian rhythm and its modification by chronic imipramine
133. Hypomania after desipramine withdrawal
134. Further mapping of central noradrenaline neuron systems: projections of the ‘subcoeruleus’ area
135. Effect of atropine scopolamine and meperidine on man
136. Central nervous system effects of hyoscine in man
137. Receptor alterations and drug tolerance
138. Comparison of cholinesterase activity in reticular formations of the lower brain stem of cat and rabbit
139. Sleep behavior elicited by electrical stimulation of cortical and subcortical structures in the cat
140. Telencephalo-diencephalic aspects of sleep mechanisms
141. Lithium reduces the number of acetylcholine receptors in skeletal muscle
142. Cholinergic transmission regulates extrajunctional acetylcholine receptors
143. Stimulation of locomotor activity following injection of dopamine into the nucleus accumbens
144. Alterations in motor activity, sleep, and biochemistry in a cycling manic-depressive patient
145. Central nervous system stimulants
146. Somnolence caused by hypothalamic lesions in monkey
147. Dextroamphetamine: cognitive and behavioral effects in normal prepubertal boys
148. Amitriptyline: long-term treatment elevates α-adrenergic and muscarinic receptor binding in mouse brain
149. Effects of amphetamine isomers and CNS catecholaminergic blockers on seizures in mice
150. Cholinergic mechanisms involved in function of mesodiencephalic activating system
151. Alerting responses and actions of atropine and cholinergic drugs
152. Mood and behavioral effects of physostigmine on humans are accompanied by elevations in plasma β-endorphin and cortisol
153. Physostigmine induction of depressive symptomatology in normal human subjects
154. β-endorphin hypersecretion in depression possible cholinergic mechanisms
155. Cholinergic challenges in affective illness: Behavioral and neuroendocrine correlates
156. β-endorphin hypersecretion in depression: possible cholinergic mechanisms
157. 9-tetrahydrocannabinol
158. Cannabis-associated psychosis with hypomanic features
159. The effects of diisopropylfluorophosphonate in schizophrenia and manic depressive psychosis
160. Abuse of antiparkinsonism drugs: feigning of extrapyramidyl symptoms to obtain Trihexyphenedyl
161. Experimental tests of hypotheses about neurochemical mechanisms underlying tolerance to the anticholinesterase diisopropylfluorophosphonate
162. Development of behavioral tolerance: A search for subcellular mechanisms
163. Mechanisms of tolerance to the anticholinesterase DFP: acetylcholine levels and dynamics in the rat brain
164. Differential effects of scopolamine and chlorpromazine on REM and NREM sleep in normal male subjects
165. The catecholamine hypothesis of affective disorders: a review of supporting evidence
166. 3H]quinuclidinyl benzilate associated with low acetylcholinesterase activity
167. Regulation of muscarinic acetylcholine receptor concentration in cloned neuroblastoma cells
168. Rebound phenomena in mania patients following physostigmine
169. Possible subsensitization of α-adrenergic receptors by chronicmonoamine oxidase inhibitor treatment in psychiatric patients
170. Cholinergic activity regulates muscarinic receptors in central nervous system cultures
171. Development and use of pharmacological probes of the CNS in man: evidence of cholinergic abnormality in primary affective illness
172. Faster cholinergic REM sleep induction in euthymic patients with primary affective illness
173. Cholinergic regulation of mood and REM sleep: potential model and marker of vulnerability to affective disorders
174. Ascending conduction in reticular activating system, with special reference to the diencephalon
175. The effect of tertiary and quaternary atropine on cortical acetylcholine output and on the electroencephalogram in cats
176. Cortical acetylcholine release and electroencephalographic arousal
177. The pathophysiology of tardive dyskinesia
178. Trans-synaptic regulation of tyrosine hydroxylase
179. A cholinergic role in the mechanism of lithium in mania
180. A polygraphic study on the effect of atropine on human nocturnal sleep
181. An effect of physostigmine on the central nervous system of rabbits, related to brain levels of norepinephrine
182. Depression
183. Myoclonic attacks induced by l-dopa and bromocriptine in parkinson patients
184. Activation of the EEG by procyclidine hydrochloride in temporallobe epilepsy
185. Methixene hydrochloride as an EEG activating agent
186. An appraisal of hyoscine as an EEG activating agent
187. Effects of anticholinergic drugs on epileptic activity from amygdala and frontal cortex
188. The effects of lithium on acetylcholine release and synthesis
189. The effects of morphine atropine and scopolamine on human subjects
190. Effects of caffeine on tactile startle in rats
191. Presynaptic effects of lithium on cholinergic synaptic transmission in aplysia neurons
192. Rapid cycling manic-depressives induced by tricyclic antidepressants
193. Norepinephrine, epinephrine and the sympathomimetic amines
194. Physostigmine test in the rabbit syndrome and tardive dyskinesia
195. 3]norepinephrine by nicotine and potassium chloride from rat brain slices
196. Tolerance to fluphenazine and supersensitivity to apomorphine in central dopaminergic systems after chronic fluphenazine decanoate treatment
197. Central and peripheral nervous effects of atropine sulfate and mepiperphenidol bromide (darstine) on human subjects
198. Pharmacologic dissociation of behavior and EEG ‘sleep patterns’ in dogs: morphine, N-allylnormorphine, and atropine
199. Observations on the effects of JB-329 (Ditran) on the electroencephalogram of man
200. Clorgycline delays phase-position of circadian neurotransmitter receptor rhythms
201. 9-tetrahydrocannabinal